RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial ...
Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides ...
Every time BI publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from Business ...
The top economic official for Chesterfield County said Thursday that he does not expect plans by DuPont de Nemours to split into three separate entities will have an impact on the factory in North ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback